Mesenchymal stromal cells (MSCs) modulate immune responses through cell contact-dependent or paracrine mechanisms and are themselves known to have low immunogenicity. Given the increasing use of both natural killer (NK) cells and MSCs in cell-based therapies, we investigated the interaction between the two cell types using the NK cell lines, KHYG-1 and NK-92, and human bone marrow-derived MSCs. NK lines were cocultured with MSCs, either directly or in a transwell system, and the effects on proliferation, interferon-gamma (IFN-γ) production, and cytolytic activity of NK cells were analyzed. Cytotoxicity was measured in a 4 h chromium release assay. MSCs did not affect the proliferation of NK cell lines but reduced IFN-γ production by KHYG-1, but not NK-92, when cocultured directly at 10:1 NK:MSC ratio. MSCs suppressed K562 lysis by both KHYG-1 and NK-92 cells in contact-free transwell cocultures but only reduced cytotoxicity of KHYG-1 and not NK-92 cells when cells were in direct contact in coculture. Immunosuppressive effects of MSCs were mediated by indoleamine-2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2) secreted by MSCs and were abrogated in the presence of IDO and PGE2 inhibitors. In the presence of MSCs, granule polarization was suppressed and induced respectively, in KHYG-1 and NK-92. Consistent with this, MSCs were susceptible to lysis by NK-92 but not KHYG-1. These studies indicate the differential crosstalk between MSCs and two highly cytotoxic NK lines and may be important when designing future cell therapy protocols with these two cell types.
PhinneyDG and ProckopDJ. (2007). Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells, 25:2896–2902.
3.
UccelliA, MorettaL and PistoiaV. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol, 8:726–736.
4.
Castro-ManrrezaME and MontesinosJJ. (2015). Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res, 2015:394917.
5.
TolarJ, Le BlancK, KeatingA and BlazarBR. (2010). Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells, 28:1446–1455.
6.
UccelliA and de RosboNK. (2015). The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci, 1351:114–126.
7.
Le Blanc K and DaviesLC. (2015). Mesenchymal stromal cells and the innate immune response. Immunol Lett, 168:140–146.
8.
AnkrumJA, OngJF and KarpJM. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol, 32:252–260.
9.
VivierE, RauletDH, MorettaA, CaligiuriMA, ZitvogelL, LanierLL, YokoyamaWM and UgoliniS. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331:44–49.
10.
BurnsLJ, WeisdorfDJ, DeForTE, VesoleDH, RepkaTL, BlazarBR, BurgerSR, Panoskaltsis-MortariA, Keever-TaylorCA, ZhangMJ and MillerJS. (2003). IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant, 32:177–186.
11.
CurtiA, RuggeriL, D'AddioA, BontadiniA, DanE, MottaMR, TrabanelliS, GiudiceV, UrbaniE, et al. (2011). Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 118:3273–3279.
12.
MillerJS, SoignierY, Panoskaltsis-MortariA, McNearneySA, YunGH, FautschSK, McKennaD, LeC, DeforTE, et al. (2005). Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105:3051–3057.
13.
HoferE and KoehlU. (2017). Natural killer cell-based cancer immunotherapies: from immune evasion to promising targeted cellular therapies. Front Immunol, 8:745.
14.
SwiftBE, WilliamsBA, KosakaY, WangXH, MedinJA, ViswanathanS, Martinez-LopezJ and KeatingA. (2012). Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica, 97:1020–1028.
15.
WilliamsBA, LawAD, RoutyB, denHollanderN, GuptaV, WangXH, ChaboureauA, ViswanathanS and KeatingA. (2017). A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget, 8:89256–89268.
16.
YouF, WangY, JiangL, ZhuX, ChenD, YuanL, AnG, MengH and YangL. (2019). A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res, 9:64–78.
17.
AraiS, MeagherR, SwearingenM, MyintH, RichE, MartinsonJ and KlingemannH. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy, 10:625–632.
18.
TonnT, SchwabeD, KlingemannHG, BeckerS, EsserR, KoehlU, SuttorpM, SeifriedE, OttmannOG and BugG. (2013). Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 15:1563–1570.
19.
SuckG, BranchDR, AravenaP, MathiesonM, HelkeS and KeatingA. (2006). Constitutively polarized granules prime KHYG-1 NK cells. Int Immunol, 18:1347–1354.
20.
SuckG, BranchDR and KeatingA. (2006). Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol, 82:355–361.
21.
SuckG, BranchDR, SmythMJ, MillerRG, VergidisJ, FahimS and KeatingA. (2005). KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol, 33:1160–1171.
22.
AggarwalS and PittengerMF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105:1815–1822.
23.
SotiropoulouPA, PerezSA, GritzapisAD, BaxevanisCN and PapamichailM. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24:74–85.
24.
RasmussonI, RingdenO, SundbergB and Le BlancK. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76:1208–1213.
25.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloG, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
26.
CuiR, RekasiH, Hepner-SchefczykM, FessmannK, PetriRM, BruderekK, BrandauS, JagerM and FloheSB. (2016). Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther, 7:88.
27.
GotherstromC, LundqvistA, DuprezIR, ChildsR, BergL and le BlancK. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 13:269–278.
28.
PoggiA, PrevostoC, MassaroAM, NegriniS, UrbaniS, PierriI, SaccardiR, GobbiM and ZocchiMR. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol, 175:6352–6360.
29.
SpaggiariGM, CapobiancoA, BecchettiS, MingariMC and MorettaL. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107:1484–1490.
30.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
31.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC and MorettaL. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
32.
Tosello-TrampontA, SuretteFA, EwaldSE and HahnYS. (2017). Immunoregulatory role of NK cells in tissue inflammation and regeneration. Front Immunol, 8:301.
33.
de Araujo FariasV, Carrillo-GalvezAB, MartinF and AndersonP. (2018). TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev, 43:25–37.
34.
HoltD, MaX, KunduN and FultonA. (2011). Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother, 60:1577–1586.
35.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB and BartholomewA. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
36.
GiulianiM, Bennaceur-GriscelliA, NanbakhshA, OudrhiriN, ChouaibS, AzzaroneB, DurrbachA and LatailladeJJ. (2014). TLR ligands stimulation protects MSC from NK killing. Stem Cells, 32:290–300.
37.
MahAY and CooperMA. (2016). Metabolic regulation of natural killer cell IFN-gamma production. Crit Rev Immunol, 36:131–147.
38.
LeongJW, SullivanRP and FehnigerTA. (2014). microRNA management of NK-cell developmental and functional programs. Eur J Immunol, 44:2862–2868.
39.
SullivanRP, FogelLA, LeongJW, SchneiderSE, WongR, RomeeR, ThaiTH, SexlV, MatkovichSJ, et al. (2013). MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol, 191:5904–5913.
40.
ThomasH, JagerM, MauelK, BrandauS, LaskS and FloheSB. (2014). Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm, 2014:143463.
41.
RajagopalanS, FuJ and LongEO. (2001). Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol, 167:1877–1881.
42.
LauwerysBR, GarotN, RenauldJC and HoussiauFA. (2000). Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol, 165:1847–1853.
43.
BrycesonYT, MarchME, BarberDF, LjunggrenHG and LongEO. (2005). Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med, 202:1001–1012.
44.
DasA and LongEO. (2010). Lytic granule polarization, rather than degranulation, is the preferred target of inhibitory receptors in NK cells. J Immunol, 185:4698–4704.
45.
EstefaniaE, FloresR, Gomez-LozanoN, AguilarH, Lopez-BotetM and VilchesC. (2007). Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol, 178:4402–4410.
46.
UhrbergM, ValianteNM, ShumBP, ShillingHG, Lienert-WeidenbachK, CorlissB, TyanD, LanierLL and ParhamP. (1997). Human diversity in killer cell inhibitory receptor genes. Immunity, 7:753–763.
47.
ChengM, ZhangJ, JiangW, ChenY and TianZ. (2012). Natural killer cell lines in tumor immunotherapy. Front Med, 6:56–66.
48.
TonnT, BeckerS, EsserR, SchwabeD and SeifriedE. (2001). Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res, 10:535–544.
49.
LeeES, LimJY, ImKI, KimN, NamYS, JeonYW and ChoSG. (2015). Adoptive transfer of Treg cells combined with mesenchymal stem cells facilitates repopulation of endogenous Treg cells in a murine acute GVHD model. PLoS One, 10:e0138846.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
